TLRY:NSD-Tilray Inc (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 1.85

Change

0.00 (0.00)%

Market Cap

USD 1.74B

Volume

0.01B

Analyst Target

USD 8.58
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-26 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
NBIX Neurocrine Biosciences Inc

+1.46 (+1.09%)

USD 13.17B
VTRS Viatris Inc

-0.16 (-1.53%)

USD 11.97B
ITCI Intracellular Th

-3.15 (-4.17%)

USD 7.97B
LNTH Lantheus Holdings Inc

+2.96 (+3.75%)

USD 5.61B
ALKS Alkermes Plc

-0.45 (-1.83%)

USD 4.17B
ALVO Alvotech

-0.55 (-4.13%)

USD 3.72B
HCM HUTCHMED DRC

-0.19 (-1.05%)

USD 3.18B
INDV Indivior PLC Ordinary Shares

-0.34 (-2.05%)

USD 2.22B
AMPH Amphastar P

-0.26 (-0.64%)

USD 2.00B
DVAX Dynavax Technologies Corporati..

-0.19 (-1.67%)

USD 1.48B

ETFs Containing TLRY

HMMJ-U:CA Horizons Marijuana Life S.. 9.14 % 0.00 %

N/A

CAD 0.09B
CNBS Amplify Seymour Cannabis .. 6.82 % 0.00 %

-0.12 (0%)

USD 0.03B
BUDX 5.76 % 0.00 %

N/A

N/A
YOLO AdvisorShares Pure Cannab.. 2.59 % 0.00 %

-0.02 (0%)

USD 0.04B
MJ Amplify Alternative Harve.. 0.00 % 0.75 %

-0.10 (0%)

USD 0.25B
SEED:CA 0.00 % 1.13 %

N/A

N/A
THCX 0.00 % 0.00 %

N/A

N/A
HMMJ:CA Global X Marijuana Life S.. 0.00 % 0.86 %

-0.21 (0%)

CAD 0.08B
MJJ 0.00 % 0.00 %

N/A

N/A
MJO 0.00 % 0.00 %

N/A

N/A
MJX 0.00 % 0.00 %

N/A

N/A
POTX 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -19.57% 36% F 27% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -19.57% 36% F 26% F
Trailing 12 Months  
Capital Gain -0.54% 61% D- 47% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.54% 61% D- 45% F
Trailing 5 Years  
Capital Gain -95.67% 23% F 7% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return -95.67% 23% F 7% C-
Average Annual (5 Year Horizon)  
Capital Gain -16.55% 43% F 20% F
Dividend Return -16.55% 43% F 20% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 93.59% 26% F 17% F
Risk Adjusted Return -17.69% 47% F 31% F
Market Capitalization 1.74B 86% B+ 78% C+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector